All In Biotech

Drug Trial Radar · NCT03636503

Rituximab + Immunotherapy in Follicular Lymphoma

A Multi-Cohort Phase 1b Clinical Trial of Rituximab in Combination With Immunotherapy in Untreated and Previously Treated Follicular Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

24

Actual

Start

Oct 30, 2018

Primary completion

Jul 23, 2021

Study completion Jul 30, 2023

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Aug 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma. The drugs involved are: * Rituximab * Utomilumab * Avelumab * PF-04518600

Conditions

  • Follicular Lymphoma

Interventions

  • RituximabDrug

    Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatment

  • UtomilumabDrug

    Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug

  • AvelumabDrug

    Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug

  • PF04518600Drug

    In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 DosingTime frame: 6 months total, assessed after each 28-day cycle
  2. Number of Participants With Complete Response Per Lugano CriteriaTime frame: Response assessed after completing treatment (6 months)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Yale New-Haven Hospital

    New Haven, Connecticut

  • Emory University

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Washington University in St. Louis

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.